Beneficial Effects on Abdominal Bloating with an Innovative Food-Grade Formulation of Curcuma longa and Boswellia serrata Extracts in Subjects with Irritable Bowel Syndrome and Small Bowel Dysbiosis.
Study Goal
The researchers aimed to evaluate the efficacy of curcumin and boswellia extracts (as Curcumin Boswellia Phytosome, CBP) combined with a Low FODMAP diet (LFD) in reducing abdominal bloating in IBS subjects with small bowel dysbiosis, compared to LFD alone.
Results Summary
The intervention group (CBP + LFD) showed a significant decrease in bloating, abdominal pain, and indican values compared to the control group (LFD alone), with a highly significant improvement in global assessment of efficacy (p < 0.0001).
Population
Subjects with irritable bowel syndrome (IBS) and small bowel dysbiosis (defined by increased urinary indican with normal urinary skatole).
Effective Dosage
500 mg twice daily of CBP.
Duration
30 days.
Interactions
None mentioned.
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
Curcumin Boswellia Phytosome (CBP) and Low FODMAP diet (LFD) | decrease | bloating | IBS subjects with small bowel dysbiosis | p < 0.0001 | showed a significant decrease | #1 |
Curcumin Boswellia Phytosome (CBP) and Low FODMAP diet (LFD) | decrease | abdominal pain | IBS subjects with small bowel dysbiosis | p < 0.0001 | showed a significant decrease | #2 |
Curcumin Boswellia Phytosome (CBP) and Low FODMAP diet (LFD) | decrease | indican values | IBS subjects with small bowel dysbiosis | p < 0.0001 | showed a significant decrease | #3 |
Curcumin Boswellia Phytosome (CBP) and Low FODMAP diet (LFD) | increase | global assessment of efficacy (GAE) | IBS subjects with small bowel dysbiosis | p < 0.0001 | showed a significantly better | #4 |
Low FODMAP diet (LFD) | decrease | bloating | subjects with irritable bowel syndrome (IBS) and small bowel dysbiosis | - | has been used to treat | #5 |
Bloating is a symptom frequently reported by subjects with irritable bowel syndrome (IBS) and small bowel dysbiosis, and Low FODMAP’s diet (LFD) has been used to treat them. Extracts of Curcumalonga and Boswelliaserrata share anti-inflammatory and antimicrobial effects that could be useful in the management of these clinical conditions. The aim of this study was to evaluate the efficacy of curcumin and boswellia extracts (as Curcumin Boswellia Phytosome, CBP) and LFD on the relief of abdominal bloating in IBS subjects with small bowel dysbiosis, in comparison to LFD alone, in a 30-day supplementation, randomized trial. IBS participants were randomized to either the intervention (500 mg bid of CBP and LFD) or control arm (LFD). Small bowel dysbiosis has been defined by an increase of urinary indican with normal urinary skatole. A total of 67 subjects were recruited. The intervention group (33 subjects) showed a significant decrease (p < 0.0001) of bloating, abdominal pain, and indican values at the end of the study, when compared to the control group (34 subjects). Moreover, the subjects of the intervention group showed a significantly better (p < 0.0001) global assessment of efficacy (GAE) as compared to controls. In conclusion, in subjects with IBS and small bowel dysbiosis, abdominal bloating can be successfully reduced with a supplementation with CBP and LFD.